You’re using a public version of DrugPatentWatch with free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 3, 2024

Ukraine: These 24 Drugs Face Patent Expirations and Generic Entry From 2024 - 2025

DrugPatentWatch® Estimated Loss of Exclusivity Dates in Ukraine

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Ukraine: These 24 Drugs Face Patent Expirations and Generic Entry From 2024 - 2025" DrugPatentWatch.com thinkBiotech, 2024 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can RUKOBIA (fostemsavir tromethamine) generic drug versions launch?

Generic name: fostemsavir tromethamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2024
Generic Entry Controlled by: Ukraine Patent 88,297
Patent Title: ПИПЕРАЗИНОВЫЕ ПРОЛЕКАРСТВА И ЗАМЕЩЕННЫЕ ПИПЕРИДИНОВЫЕ АНТИВИРУСНЫЕ СРЕДСТВА;ПІПЕРАЗИНОВІ ПРОЛІКИ І ЗАМІЩЕНІ ПІПЕРИДИНОВІ АНТИВІРУСНІ ЗАСОБИ (PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS)

RUKOBIA is a drug marketed by Viiv Hlthcare. There are three patents protecting this drug.

This drug has thirty-nine patent family members in thirty countries.

See drug price trends for RUKOBIA.

The generic ingredient in RUKOBIA is fostemsavir tromethamine. One supplier is listed for this generic product. Additional details are available on the fostemsavir tromethamine profile page.

When can SYNJARDY (empagliflozin; metformin hydrochloride) generic drug versions launch?

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Ukraine Patent 89,040
Patent Title: ЗАМЕЩЕННЫЕ ГЛЮКОПИРАНОЗИЛОМ БЕНЗОЛЬНЫЕ ПРОИЗВОДНЫЕ, ЛЕКАРСТВЕННОЕ СРЕДСТВО, КОТОРОЕ СОДЕРЖИТ ЭТИ СОЕДИНЕНИЯ;ЗАМІЩЕНІ ГЛЮКОПІРАНОЗИЛОМ БЕНЗОЛЬНІ ПОХІДНІ, ЛІКАРСЬКИЙ ЗАСІБ, ЯКИЙ МІСТИТЬ ЦІ СПОЛУКИ (GLUCOPYRANOSYL-SUBSTITUTED BENZOL DERIVATIVES, DRUGS CONTAINING SAID COMPOUNDS)

Drug Price Trends for SYNJARDY
SYNJARDY is a drug marketed by Boehringer Ingelheim. There are ten patents protecting this drug and two Paragraph IV challenges.

This drug has two hundred and thirty-four patent family members in forty-five countries. There has been litigation on patents covering SYNJARDY

See drug price trends for SYNJARDY.

The generic ingredient in SYNJARDY is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

When can SYNJARDY XR (empagliflozin; metformin hydrochloride) generic drug versions launch?

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Ukraine Patent 89,040
Patent Title: ЗАМЕЩЕННЫЕ ГЛЮКОПИРАНОЗИЛОМ БЕНЗОЛЬНЫЕ ПРОИЗВОДНЫЕ, ЛЕКАРСТВЕННОЕ СРЕДСТВО, КОТОРОЕ СОДЕРЖИТ ЭТИ СОЕДИНЕНИЯ;ЗАМІЩЕНІ ГЛЮКОПІРАНОЗИЛОМ БЕНЗОЛЬНІ ПОХІДНІ, ЛІКАРСЬКИЙ ЗАСІБ, ЯКИЙ МІСТИТЬ ЦІ СПОЛУКИ (GLUCOPYRANOSYL-SUBSTITUTED BENZOL DERIVATIVES, DRUGS CONTAINING SAID COMPOUNDS)

Drug Price Trends for SYNJARDY XR
SYNJARDY XR is a drug marketed by Boehringer Ingelheim. There are nine patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and eight patent family members in forty-one countries. There has been litigation on patents covering SYNJARDY XR

See drug price trends for SYNJARDY XR.

The generic ingredient in SYNJARDY XR is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

When can IMPLANON (etonogestrel) generic drug versions launch?

Generic name: etonogestrel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 19, 2024
Generic Entry Controlled by: Ukraine Patent 86,404
Patent Title: РЕНТГЕНОКОНТРАСТНОЕ СРЕДСТВО СНАБЖЕНИЯ ЛЕКАРСТВА;РЕНТГЕНОКОНТРАСТНИЙ ЗАСІБ ПОСТАЧАННЯ ЛІКІВ (Normal;heading 1;heading 2;X-RAY VISIBLE DRUG DELIVERY DEVICE)

IMPLANON is a drug marketed by Organon. There is one patent protecting this drug.

This drug has thirty-three patent family members in twenty-seven countries.

The generic ingredient in IMPLANON is etonogestrel. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the etonogestrel profile page.

When can OGSIVEO (nirogacestat hydrobromide) generic drug versions launch?

Generic name: nirogacestat hydrobromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 23, 2024
Generic Entry Controlled by: Ukraine Patent 83,899
Patent Title: СОЕДИНЕНИЯ ИМИДАЗОЛА ДЛЯ ЛЕЧЕНИЯ НЕЙРОДЕГЕНЕРАТИВНЫХ РАССТРОЙСТВ;СПОЛУКИ ІМІДАЗОЛУ ДЛЯ ЛІКУВАННЯ НЕЙРОДЕГЕНЕРАТИВНИХ РОЗЛАДІВ (IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS)

OGSIVEO is a drug marketed by Springworks. There are twelve patents protecting this drug.

This drug has sixty-six patent family members in forty-four countries.

See drug price trends for OGSIVEO.

The generic ingredient in OGSIVEO is nirogacestat hydrobromide. One supplier is listed for this generic product. Additional details are available on the nirogacestat hydrobromide profile page.

When can DUAVEE (bazedoxifene acetate; estrogens, conjugated) generic drug versions launch?

Generic name: bazedoxifene acetate; estrogens, conjugated
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 07, 2024
Generic Entry Controlled by: Ukraine Patent 85,703
Patent Title: КРИСТАЛІЧНИЙ ПОЛІМОРФ БАЗЕДОКСИФЕНУ АЦЕТАТУ[КРИСТАЛЛИЧЕСКИЙ ПОЛИМОРФ БАЗЕДОКСИФЕНА АЦЕТАТА (CRYSTALLINE POLYMORPH OF BAZEDOXIFENE ACETATE)

Drug Price Trends for DUAVEE
DUAVEE is a drug marketed by Wyeth Pharms. There are two patents protecting this drug.

This drug has twenty-two patent family members in twenty countries.

See drug price trends for DUAVEE.

The generic ingredient in DUAVEE is bazedoxifene acetate; estrogens, conjugated. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the bazedoxifene acetate; estrogens, conjugated profile page.

When can NATAZIA (dienogest; estradiol valerate) generic drug versions launch?

Generic name: dienogest; estradiol valerate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 20, 2024
Generic Entry Controlled by: Ukraine Patent 83,915
Patent Title: МНОГОФАЗНЫЙ ПРЕПАРАТ ДЛЯ КОНТРАЦЕПЦИИ НА ОСНОВЕ НАТУРАЛЬНОГО ЭСТРОГЕНА;БАГАТОФАЗНИЙ ПРЕПАРАТ ДЛЯ КОНТРАЦЕПЦІЇ НА ОСНОВІ НАТУРАЛЬНОГО ЕСТРОГЕНУ (MULTI-PHASE CONTRACEPTIVE PREPARATION BASED ON A NATURAL ESTROGEN)

Drug Price Trends for NATAZIA
NATAZIA is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has ninety patent family members in thirty-nine countries. There has been litigation on patents covering NATAZIA

See drug price trends for NATAZIA.

The generic ingredient in NATAZIA is dienogest; estradiol valerate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the dienogest; estradiol valerate profile page.

When can INCRUSE ELLIPTA (umeclidinium bromide) generic drug versions launch?

Generic name: umeclidinium bromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 27, 2024
Generic Entry Controlled by: Ukraine Patent 95,768
Patent Title: АНТАГОНИСТЫ МУСКАРИНОВЫХ РЕЦЕПТОРОВ АЦЕТИЛХОЛИНА;АНТАГОНІСТИ МУСКАРИНОВИХ РЕЦЕПТОРІВ АЦЕТИЛХОЛІНУ (MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS)

Drug Price Trends for INCRUSE ELLIPTA
INCRUSE ELLIPTA is a drug marketed by

This drug has one hundred and seventy-seven patent family members in thirty-nine countries. There has been litigation on patents covering INCRUSE ELLIPTA

See drug price trends for INCRUSE ELLIPTA .

The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the umeclidinium bromide profile page.

When can VIZIMPRO (dacomitinib) generic drug versions launch?

Generic name: dacomitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 06, 2024
Generic Entry Controlled by: Ukraine Patent 85,706
Patent Title: 4-ФЕНІЛАМІНОХІНАЗОЛІН-6-ІЛАМІДИ[4-ФЕНИЛАМИНОХИНАЗОЛИН-6-ИЛАМИДЫ (4-PHENYLAMINOQUINAZOLIN-6-YL AMIDES)

VIZIMPRO is a drug marketed by Pfizer. There are four patents protecting this drug.

This drug has ninety-two patent family members in forty-eight countries.

See drug price trends for VIZIMPRO.

The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this generic product. Additional details are available on the dacomitinib profile page.

When can CAPRELSA (vandetanib) generic drug versions launch?

Generic name: vandetanib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 21, 2024
Generic Entry Controlled by: Ukraine Patent 81,732
Patent Title: ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ZD6474;ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ ZD6474 (PHARMACEUTICAL COMPOSITION COMPRISING ZD6474)

CAPRELSA is a drug marketed by Genzyme Corp. There is one patent protecting this drug.

This drug has forty patent family members in thirty-three countries.

See drug price trends for CAPRELSA.

The generic ingredient in CAPRELSA is vandetanib. One supplier is listed for this generic product. Additional details are available on the vandetanib profile page.

When can KOMBIGLYZE XR (metformin hydrochloride; saxagliptin hydrochloride) generic drug versions launch?

Generic name: metformin hydrochloride; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Ukraine Patent 88,168
Patent Title: ПРЕПАРАТ В ВИДЕ ТАБЛЕТКИ САКСАГЛИПТИНА С ПОКРЫТИЕМ И СПОСОБ ЕГО ИЗГОТОВЛЕНИЯ;ПРЕПАРАТ У ВИГЛЯДІ ТАБЛЕТКИ САКСАГЛІПТИНУ З ПОКРИТТЯМ І СПОСІБ ЙОГО ВИГОТОВЛЕННЯ (COATED TABLET FORMULATION COMPRISING SAXAGLIPITIN AND METHOD FOR FORMING THEREOF)

Drug Price Trends for KOMBIGLYZE XR
KOMBIGLYZE XR is a drug marketed by Astrazeneca Ab. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-seven patent family members in forty-one countries. There has been litigation on patents covering KOMBIGLYZE XR

See drug price trends for KOMBIGLYZE XR.

The generic ingredient in KOMBIGLYZE XR is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.

When can ONGLYZA (saxagliptin hydrochloride) generic drug versions launch?

Generic name: saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Ukraine Patent 88,168
Patent Title: ПРЕПАРАТ В ВИДЕ ТАБЛЕТКИ САКСАГЛИПТИНА С ПОКРЫТИЕМ И СПОСОБ ЕГО ИЗГОТОВЛЕНИЯ;ПРЕПАРАТ У ВИГЛЯДІ ТАБЛЕТКИ САКСАГЛІПТИНУ З ПОКРИТТЯМ І СПОСІБ ЙОГО ВИГОТОВЛЕННЯ (COATED TABLET FORMULATION COMPRISING SAXAGLIPITIN AND METHOD FOR FORMING THEREOF)

Drug Price Trends for ONGLYZA
ONGLYZA is a drug marketed by Astrazeneca Ab. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and twenty-seven patent family members in forty-one countries. There has been litigation on patents covering ONGLYZA

See drug price trends for ONGLYZA.

The generic ingredient in ONGLYZA is saxagliptin hydrochloride. There are fifteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the saxagliptin hydrochloride profile page.

When can ERIVEDGE (vismodegib) generic drug versions launch?

Generic name: vismodegib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2024
Generic Entry Controlled by: Ukraine Patent 96,565
Patent Title: ПИРИДИЛЬНЫЕ ИНГИБИТОРЫ ХЕДЖХОГОВСКОЙ ПЕРЕДАЧИ СИГНАЛА;ПІРИДИЛЬНІ ІНГІБІТОРИ ХЕДЖХОГІВСЬКОЇ ПЕРЕДАЧІ СИГНАЛУ (PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING)

ERIVEDGE is a drug marketed by Genentech. There are three patents protecting this drug.

This drug has fifty-three patent family members in twenty-four countries.

See drug price trends for ERIVEDGE.

The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this generic product. Additional details are available on the vismodegib profile page.

When can YONDELIS (trabectedin) generic drug versions launch?

Generic name: trabectedin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 29, 2024
Generic Entry Controlled by: Ukraine Patent 91,032
Patent Title: КОМПОЗИЦІЇ, ЩО МІСТЯТЬ ЕКТИНЕСАЙДИН І ДИСАХАРИД[КОМПОЗИЦИИ, КОТОРЫЕ СОДЕРЖАТ ЭКТИНЭСАЙДИН И ДИСАХАРИД (FORMULATIONS COMPRISING ECTEINASCIDIN AND A DISACCHARIDE)

YONDELIS is a drug marketed by Janssen Prods. There is one patent protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has forty-four patent family members in thirty-six countries. There has been litigation on patents covering YONDELIS

See drug price trends for YONDELIS.

The generic ingredient in YONDELIS is trabectedin. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the trabectedin profile page.

When can DUTREBIS (lamivudine; raltegravir potassium) generic drug versions launch?

Generic name: lamivudine; raltegravir potassium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 03, 2024
Generic Entry Controlled by: Ukraine Patent 87,884
Patent Title: БЕЗВОДНАЯ КРИСТАЛЛИЧЕСКАЯ КАЛИЕВАЯ СОЛЬ ИНГИБИТОРА ВИЧ-ИНТЕГРАЗЫ;БЕЗВОДНА КРИСТАЛІЧНА КАЛІЄВА СІЛЬ ІНГІБІТОРА ВІЛ-ІНТЕГРАЗИ (POTASSIUM SALT OF AN HIV INTEGRASE INHIBITOR)

DUTREBIS is a drug marketed by Merck Sharp Dohme. There are five patents protecting this drug.

This drug has ninety-five patent family members in forty-three countries.

The generic ingredient in DUTREBIS is lamivudine; raltegravir potassium. There are twenty-nine drug master file entries for this API. Additional details are available on the lamivudine; raltegravir potassium profile page.

When can ISENTRESS (raltegravir potassium) generic drug versions launch?

Generic name: raltegravir potassium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 03, 2024
Generic Entry Controlled by: Ukraine Patent 87,884
Patent Title: БЕЗВОДНАЯ КРИСТАЛЛИЧЕСКАЯ КАЛИЕВАЯ СОЛЬ ИНГИБИТОРА ВИЧ-ИНТЕГРАЗЫ;БЕЗВОДНА КРИСТАЛІЧНА КАЛІЄВА СІЛЬ ІНГІБІТОРА ВІЛ-ІНТЕГРАЗИ (POTASSIUM SALT OF AN HIV INTEGRASE INHIBITOR)

Drug Price Trends for ISENTRESS
ISENTRESS is a drug marketed by Msd Sub Merck. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-five patent family members in forty-five countries.

See drug price trends for ISENTRESS.

The generic ingredient in ISENTRESS is raltegravir potassium. There are five drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the raltegravir potassium profile page.

When can NEURACEQ (florbetaben f-18) generic drug versions launch?

Generic name: florbetaben f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 17, 2024
Generic Entry Controlled by: Ukraine Patent 91,996
Patent Title: ПРОИЗВОДНЫЕ СТИЛЬБЕНА И ИХ ПРИМЕНЕНИЕ ДЛЯ СВЯЗЫВАНИЯ И ВИЗУАЛИЗАЦИИ АМИЛОИДНЫХ БЛЯШЕК;ПОХІДНІ СТИЛЬБЕНУ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЗВ'ЯЗУВАННЯ ТА ВІЗУАЛІЗАЦІЇ АМІЛОЇДНИХ БЛЯШОК (STILBENE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES)

NEURACEQ is a drug marketed by Life Molecular. There is one patent protecting this drug.

This drug has thirty-five patent family members in twenty-seven countries.

The generic ingredient in NEURACEQ is florbetaben f-18. One supplier is listed for this generic product. Additional details are available on the florbetaben f-18 profile page.

When can BELRAPZO (bendamustine hydrochloride) generic drug versions launch?

Generic name: bendamustine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 14, 2025
Generic Entry Controlled by: Ukraine Patent 94,036
Patent Title: ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ БЕНДАМУСТИНА, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛИОФИЛИЗАЦИИ;ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ БЕНДАМУСТИНУ, ПРИЗНАЧЕНА ДЛЯ ЛІОФІЛІЗАЦІЇ (BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS FOR LYOPHILISATION)

BELRAPZO is a drug marketed by Eagle Pharms. There are eight patents protecting this drug. Six tentatively approved generics are ready to enter the market.

This drug has sixty-four patent family members in thirty countries.

See drug price trends for BELRAPZO.

The generic ingredient in BELRAPZO is bendamustine hydrochloride. There are twenty-three drug master file entries for this API. Ten suppliers are listed for this generic product. Additional details are available on the bendamustine hydrochloride profile page.

When can BENDEKA (bendamustine hydrochloride) generic drug versions launch?

Generic name: bendamustine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 14, 2025
Generic Entry Controlled by: Ukraine Patent 94,036
Patent Title: ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ БЕНДАМУСТИНА, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛИОФИЛИЗАЦИИ;ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ БЕНДАМУСТИНУ, ПРИЗНАЧЕНА ДЛЯ ЛІОФІЛІЗАЦІЇ (BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS FOR LYOPHILISATION)

BENDEKA is a drug marketed by Eagle Pharms. There are seventeen patents protecting this drug and one Paragraph IV challenge. Six tentatively approved generics are ready to enter the market.

This drug has one hundred and twelve patent family members in thirty-one countries. There has been litigation on patents covering BENDEKA

See drug price trends for BENDEKA.

The generic ingredient in BENDEKA is bendamustine hydrochloride. There are twenty-three drug master file entries for this API. Ten suppliers are listed for this generic product. Additional details are available on the bendamustine hydrochloride profile page.

When can VOCABRIA (cabotegravir sodium) generic drug versions launch?

Generic name: cabotegravir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 21, 2025
Generic Entry Controlled by: Ukraine Patent 96,568
Patent Title: ПОЛІЦИКЛІЧНЕ ПОХІДНЕ КАРБАМОЇЛПІРИДОНУ ЯК ІНГІБОР ВІЛ-ІНТЕГРАЗИ[ПОЛИЦИКЛИЧЕСКОЕ ПРОИЗВОДНОЕ КАРБАМОИЛПИРИДОНА КАК ИНГИБИТОР ВИЧ-ИНТЕГРАЗЫ (POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE AS HIV-INTEGRASE INHIBITOR)

VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.

This drug has one hundred and twenty-three patent family members in thirty-three countries.

The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.

When can CORLANOR (ivabradine) generic drug versions launch?

Generic name: ivabradine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2025
Generic Entry Controlled by: Ukraine Patent 86,595
Patent Title: ГАММА-КРИСТАЛЛИЧЕСКАЯ ФОРМА ГИДРОХЛОРИДА ИВАБРАДИНА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ЕЕ СОДЕРЖИТ;ГАММА-КРИСТАЛІЧНА ФОРМА ГІДРОХЛОРИДУ ІВАБРАДИНУ, СПОСІБ ЇЇ ОДЕРЖАННЯ І ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЯКА ЇЇ МІСТИТЬ (GAMMA-CRYSTALLINE FORM OF THE CHLOROHYDRATE OF IVABRADINE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT)

Drug Price Trends for CORLANOR
CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR

See drug price trends for CORLANOR.

The generic ingredient in CORLANOR is ivabradine. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivabradine profile page.

When can CORLANOR (ivabradine hydrochloride) generic drug versions launch?

Generic name: ivabradine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2025
Generic Entry Controlled by: Ukraine Patent 80,904
Patent Title: CRYSTALLINE FORM BETA OF THE CHLORHYDRATE OF IVABRADINE, PROCESS FOR ITS PREPARATION AND PHARAMCETUICAL COMPOSITION CONTAINING IT

Drug Price Trends for CORLANOR
CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR

See drug price trends for CORLANOR.

The generic ingredient in CORLANOR is ivabradine hydrochloride. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivabradine hydrochloride profile page.

When can XIFAXAN (rifaximin) generic drug versions launch?

Generic name: rifaximin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 03, 2025
Generic Entry Controlled by: Ukraine Patent 89,809
Patent Title: НОВЫЕ ПОЛИМОРФНЫЕ ФОРМЫ РИФАКСИМИНА, СПОСОБ ИХ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЕ В МЕДИЦИНСКИХ ПРЕПАРАТАХ;НОВІ ПОЛІМОРФНІ ФОРМИ РИФАКСИМІНУ, СПОСІБ ЇХ ОТРИМАННЯ ТА ЇХ ЗАСТОСУВАННЯ У МЕДИЧНИХ ПРЕПАРАТАХ (NEW POLYMORPHOUS FORMS OF RIFAXIMIN, PROCESS FOR THEIR PRODUCTION AND USE THEREOF IN THE MEDICINAL)

Drug Price Trends for XIFAXAN
XIFAXAN is a drug marketed by Salix Pharms. There are twenty-nine patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has two hundred and six patent family members in thirty-nine countries. There has been litigation on patents covering XIFAXAN

See drug price trends for XIFAXAN.

The generic ingredient in XIFAXAN is rifaximin. There are fourteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the rifaximin profile page.

When can NEXAVAR (sorafenib tosylate) generic drug versions launch?

Generic name: sorafenib tosylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 07, 2025
Generic Entry Controlled by: Ukraine Patent 93,673
Patent Title: ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ СОДЕРЖИТ ОМЕГА-КАРБОКСИАРИЛЗАМЕЩЕННУЮ ДИФЕНИЛМОЧЕВИНУ, ДЛЯ ЛЕЧЕНИЯ PAKA;ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЯКА МІСТИТЬ ОМЕГА-КАРБОКСІАРИЛЗАМІЩЕНУ ДИФЕНІЛСЕЧОВИНУ, ДЛЯ ЛІКУВАННЯ РАКУ (PHARMACEUTICAL COMPOSITION COMPRISING AN OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREA FOR THE TREATMENT OF CANCER)

NEXAVAR is a drug marketed by Bayer Hlthcare. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and four patent family members in thirty-nine countries. There has been litigation on patents covering NEXAVAR

See drug price trends for NEXAVAR.

The generic ingredient in NEXAVAR is sorafenib tosylate. There are thirteen drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the sorafenib tosylate profile page.

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.